Cabergoline
Dostinex (cabergoline) is a small molecule pharmaceutical. Cabergoline was first approved as Dostinex on 1996-12-23. It is used to treat adenoma, hyperprolactinemia, and parkinson disease in the USA. It is known to target 5-hydroxytryptamine receptor 2A, D(1A) dopamine receptor, 5-hydroxytryptamine receptor 1A, alpha-1A adrenergic receptor, alpha-2A adrenergic receptor, D(1B) dopamine receptor, D(3) dopamine receptor, 5-hydroxytryptamine receptor 2C, alpha-2B adrenergic receptor, 5-hydroxytryptamine receptor 2B, D(2) dopamine receptor, alpha-2C adrenergic receptor, D(4) dopamine receptor, 5-hydroxytryptamine receptor 1B, and 5-hydroxytryptamine receptor 1D.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cabergoline
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| DOSTINEX | Mylan | N-020664 DISCN | 1996-12-23 | 1 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| cabergoline | ANDA | 2023-05-15 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J8515 | Cabergoline, oral, 0.25 mg |
Clinical
Clinical Trials
57 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | 1 | 6 | 14 | 3 | 5 | 28 |
| Hepatitis c | D006526 | B19.2 | 3 | 3 | 5 | 2 | 1 | 14 | |
| Hiv | D006678 | O98.7 | — | 1 | — | 1 | 1 | 3 | |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | — | — | 1 | 1 | 2 |
| Hepatitis | D006505 | HP_0012115 | K75.9 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | 1 | 2 | 2 | — | — | 5 |
| Hepacivirus | D016174 | 1 | 1 | 1 | — | — | 2 | ||
| Chronic hepatitis b | D019694 | EFO_0004197 | B18.1 | — | — | 1 | — | 1 | 2 |
| Menopause | D008593 | EFO_0003922 | N95 | — | — | 1 | — | — | 1 |
| Coinfection | D060085 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 3 | 1 | — | — | — | 3 | ||
| Experimental liver cirrhosis | D008106 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Papillomavirus infections | D030361 | 2 | — | — | — | — | 2 | ||
| Thrombocytopenia | D013921 | HP_0001873 | D69.6 | 1 | — | — | — | — | 1 |
| Liver transplantation | D016031 | EFO_0010682 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | — | — | — | 2 | 2 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | CABERGOLINE |
| INN | cabergoline |
| Description | Cabergoline is an N-acylurea that is (8R)-ergoline-8-carboxamide in which the hydrogen attached to the piperidine nitrogen (position 6) is substituted by an allyl group and the hydrogens attached to the carboxamide nitrogen are substituted by a 3-(dimethylamino)propyl group and an N-ethylcarbamoyl group. A dopamine D2 receptor agonist, cabergoline is used in the management of Parkinson's disease and of disorders associated with hyperprolactinaemia. It has a role as a dopamine agonist, an antiparkinson drug and an antineoplastic agent. |
| Classification | Small molecule |
| Drug class | ergot alkaloid deriviatives |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)NCC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21 |
Identifiers
| PDB | — |
| CAS-ID | 81409-90-7 |
| RxCUI | 47579 |
| ChEMBL ID | CHEMBL1201087 |
| ChEBI ID | 3286 |
| PubChem CID | 54746 |
| DrugBank | DB00248 |
| UNII ID | LL60K9J05T (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
HTR2A
HTR2A
DRD1
DRD1
HTR1A
HTR1A
ADRA1A
ADRA1A
ADRA2A
ADRA2A
DRD5
DRD5
DRD3
DRD3
HTR2C
HTR2C
ADRA2B
ADRA2B
HTR2B
HTR2B
DRD2
DRD2
ADRA2C
ADRA2C
DRD4
DRD4
HTR1B
HTR1B
HTR1D
HTR1D
Organism
Homo sapiens
Gene name
HTR2A
Gene synonyms
HTR2
NCBI Gene ID
Protein name
5-hydroxytryptamine receptor 2A
Protein synonyms
5-HT2 receptor, 5-hydroxytryptamine (serotonin) receptor 2A, G protein-coupled, serotonin 5-HT-2A receptor, Serotonin receptor 2A
Uniprot ID
Mouse ortholog
Htr2a (15558)
5-hydroxytryptamine receptor 2A (P35363)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,439 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
10,101 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more